MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3

Anti-Cancer Drugs

Volumn 25, Issue 7, 2014, Pages 799-809

  Wu, Huijuan ^a   Xiao, Zhenghua ^c   Zhang, Hua ^b   Wang, Ke ^a   Liu, Wenxin ^a   Hao, Quan ^a  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Akt3; cisplatin resistance; microRNA; miR 489; ovarian cancer

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CISPLATIN; MICRORNA; MICRORNA 489; PROTEIN AKT3; PROTEIN KINASE B; UNCLASSIFIED DRUG; AKT3 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; MIRN489 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84903816867     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000107     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Januchowski R,Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int 2013; 2013:241763.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
4. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003; 100:9779-9784. (Pubitemid 37087018)
5. Zhang LY, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem 2013; 288:4035-4047.
6. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003; 113:25-36. (Pubitemid 36411957)
7. Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-355. (Pubitemid 39265675)
8. Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou C, et al. A miR-200b/200c/429-binding site polymorphism in the 30 untransl ated region of the AP-2alpha gene is associated with cisplatin resistance. PLoS One 2011; 6:e29043.
9. Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011; 30:55.
10. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012; 29:384-391.
11. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.
12. Feng B, Wang R, Song HZ, Chen LB. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 2012; 118:3365-3376.
13. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011; 20:104-118.
14. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008; 111:478-486.
15. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD,Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68:425-433. (Pubitemid 351380068)
16. Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012; 586:1279-1286.
17. Sun YX, Yang J, Wang PY, Li YJ, Xie SY, Sun RP. Cisplatin regulates SHSY5Y cell growth through downregulation of BDNF via miR-16. Oncol Rep 2013; 30:2343-2349.
18. Iida K, Fukushi J, Matsumoto Y, Oda Y, Takahashi Y, Fujiwara T, et al. miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectoderma l tumor. Cancer Cell Int 2013; 13:21.
19. Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is a ssociated with a favourable clinical outcome. Br J Cancer 2012; 107:967-976.
20. Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, et al. MicroRNA-30c inhibits human breast t umour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013; 4:1393.
21. Miller TE,Ghoshal K,Ramaswamy B,Roy S,Datta J,Shapiro CL,et al,MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1,J Biol Chem,2008,283,29897-29903.
22. Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, et al. miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer 2010; 103:877-884.
23. Sung JS, Park KH, Kim ST, Kim YH. Discovery and evaluation of polymor phisms in the AKT2 and AKT3 promoter regions for risk of Korean lung cancer. Genomics Inform 2012; 10:167-174.
24. Wei W, He HB, Zhang WY, Zhang HX, Bai JB, Liu HZ, et al. miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development. Cell Death Dis 2013; 4:e668.
25. Liu S, Patel SH, Ginestier C, Ibarra I, Martin-Trevino R, Bai S, et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet 2012; 8:e1002751.
26. Yang YI, Lee KT, Park HJ, Kim TJ, Choi YS, Shih IEM, et al. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFkappaB pathway. Carcinogenesis 2012; 33:2488-2498.
27. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 2010; 70:6670- 6681.